FDA Approved: CAMPATH — Supplemental Application (Genzyme Corporation)

View source ↗

Summary

The FDA approved a supplemental application for CAMPATH (alemtuzumab) from Genzyme Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Chronic Lymphocytic Leukemia

Drugs mentioned

• CAMPATH (ALEMTUZUMAB)

Snippet

SUPPL AP for CAMPATH (ALEMTUZUMAB)